GuidelinePractical radiation oncology
Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline.
Guideline in Practical radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 196 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.Journal for immunotherapy of cancer · 2022Guideline
- Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- European lung cancer congress 2026 - the thoracic radiation oncologist's view.Clinical and translational radiation oncology · 2026Article
- Article
- Review
- BraMARS: An Interpretable Histopathology-Driven Deep Learning Model for Brain Metastasis Risk Stratification in Surgically Resected Limited-Stage SCLC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Prophylactic Cranial Irradiation and Survival in Limited-Stage SCLC: A Multicenter Real-World Analysis From the Canadian SCLC Database (CASCADE).JTO clinical and research reports · 2026Article
- Prophylactic cranial irradiation in the era of immunotherapy in extensive-stage small cell lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Review of Management of Clinical Stage I Small Cell Lung Cancer: The Rising Role of Surgical Resection.Cancers · 2026Review
- Addressing Unmet Needs in the Management of Small Cell Lung Cancer: Treatment of Brain Metastases, Quality of Life, and the Role of Real-World Evidence.Current treatment options in oncology · 2026Review
- Value of [European journal of nuclear medicine and molecular imaging · 2026Article
- Elective nodal irradiation of high-risk regions is superior to involved field radiotherapy for limited-stage small cell lung cancer: a propensity score-matched retrospective study.Radiation oncology (London, England) · 2026Article
- Deep-Learning-Based 3D Dose Distribution Prediction for VMAT Lung Cancer Treatment Using an Enhanced UNet3D Architecture with Composite Loss Functions.Bioengineering (Basel, Switzerland) · 2026Article
- Failure patterns and the influence of the TNM staging systems on prognosis in limited disease small cell lung Cancer (SCLC): the Turkish Oncology Group (TOG) study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Clinical outcomes of thoracic radiotherapy in combination with chemoimmunotherapy in elderly patients with extensive-stage small cell lung cancer.Precision radiation oncology · 2026Article
- Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC.Antibodies (Basel, Switzerland) · 2026Review
- Synchronous low-grade myofibroblastic sarcoma and small cell lung cancer in a patient with situs inversus totalis: a case report and literature review.Frontiers in oncology · 2026Article
- Clinical impact of first-line chemotherapy combined with immune checkpoint inhibitors for limited-stage small cell lung cancer patients: a real-world propensity score matching study.Frontiers in immunology · 2026Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 16 institutions in 3 countries.
Funding
Abstract
purposeSeveral sentinel phase III randomized trials have recently been published challenging traditional radiation therapy (RT) practices for small cell lung cancer (SCLC). This American Society for Radiation Oncology guideline reviews the evidence for thoracic RT and prophylactic cranial irradiation (PCI) for both limited-stage (LS) and extensive-stage (ES) SCLC.
methodsThe American Society for Radiation Oncology convened a task force to address 4 key questions focused on indications, dose fractionation, techniques and timing of thoracic RT for LS-SCLC, the role of stereotactic body radiation therapy (SBRT) compared with conventional RT in stage I or II node negative SCLC, PCI for LS-SCLC and ES-SCLC, and thoracic consolidation for ES-SCLC. Recommendations were based on a systematic literature review and created using a consensus-building methodology and system for grading evidence quality and recommendation strength.
resultsThe task force strongly recommends definitive thoracic RT administered once or twice daily early in the course of treatment for LS-SCLC. Adjuvant RT is conditionally recommended in surgically resected patients with positive margins or nodal metastases. Involved field RT delivered using conformal advanced treatment modalities to postchemotherapy volumes is also strongly recommended. For patients with stage I or II node negative disease, SBRT or conventional fractionation is strongly recommended, and chemotherapy should be delivered before or after SBRT. In LS-SCLC, PCI is strongly recommended for stage II or III patients who responded to chemoradiation, conditionally not recommended for stage I patients, and should be a shared decision for patients at higher risk of neurocognitive toxicities. In ES-SCLC, radiation oncologist consultation for consideration of PCI versus magnetic resonance surveillance is strongly recommended. Lastly, the use of thoracic RT is strongly recommended in select patients with ES-SCLC after chemotherapy treatment, including a conditional recommendation in those responding to chemotherapy and immunotherapy.
conclusionsRT plays a vital role in both LS-SCLC and ES-SCLC. These guidelines inform best clinical practices for local therapy in SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.